ALLON INITIATES TRIAL OF AL-108 FOR ALZHEIMER'S

Allon Therapeutics announced it has begun dosing in a Phase Ib human clinical trial evaluating AL-108 as a treatment for Alzheimer's disease.

The study is a double-blind, placebo-controlled, randomized trial to evaluate the safety, tolerability and pharmacokinetics of seven days of intranasal administration of AL-108 in healthy elderly subjects. This trial uses repeated daily dosing and will support Phase II trials using prolonged administration of AL-108 to test efficacy.

Dosing will be concluded in the fourth quarter of this year, and results will be analyzed and released shortly after. A Phase Ia trial has already demonstrated that a single ascending intranasal dose of up to 15 mg was safe and well-tolerated in healthy adults.

Allon has shown in preclinical animal studies that AL-108 is effective in targeting both amyloid plaques and neurofibrillary tangles in the brain, two pathologies most closely correlated with Alzheimer's disease in humans. No drug on the market today has any effect on these plaques and tangles.